Biodexa Pharmaceuticals (NASDAQ:BDRX) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Biodexa Pharmaceuticals (NASDAQ:BDRX) from a hold rating to a sell rating in a report issued on Monday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 6.5%

Shares of BDRX opened at $0.61 on Monday. Biodexa Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $19.30. The stock has a fifty day moving average price of $1.21 and a 200-day moving average price of $3.85.

Biodexa Pharmaceuticals shares are going to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last issued its quarterly earnings results on Friday, March 27th. The company reported $0.70 earnings per share for the quarter. As a group, analysts forecast that Biodexa Pharmaceuticals will post -1.25 earnings per share for the current year.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.